Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

Official title

Phase 2 Study of Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

Overview

The goal of this clinical study is to determine whether monitoring ctDNA and treating patients who become ctDNA-positive with abemaciclib can help prevent the recurrence of hormone receptor-positive, HER2-negative breast cancer after curative surgery and standard therapy. The study will also assess the safety of abemaciclib and the medical problems that may occur during treatment. Participants will receive routine follow-up after surgery, undergo regular blood tests to measure ctDNA, and, if ctDNA becomes positive, receive abemaciclib for a defined treatment period with scheduled clinic visits for examinations and safety assessments. Researchers will evaluate recurrence-free survival, distant recurrence-free survival, adverse events, the time between ctDNA positivity and clinical recurrence, and the rate of ctDNA clearance at the end of abemaciclib therapy.

Detailed description

The purpose of this clinical study is to investigate whether identifying molecular relapse through ctDNA monitoring and initiating abemaciclib treatment at the time of ctDNA positivity can reduce the risk of recurrence in patients with hormone receptor-positive, HER2-negative early breast cancer who have completed curative surgery and standard adjuvant therapy. The study also aims to evaluate the safety profile of abemaciclib in this early-stage setting and to clarify how patients tolerate the treatment over time. Participants will undergo routine postoperative surveillance, including scheduled imaging and laboratory testing, as well as regular blood sampling for ctDNA analysis. When ctDNA becomes detectable, indicating minimal residual disease, participants will begin a predefined course of abemaciclib and attend clinic visits at regular intervals for physical examinations, toxicity assessments, and laboratory monitoring.

In addition to determining whether early intervention with abemaciclib can delay or prevent clinical recurrence, researchers will examine several key outcomes. These include invasive disease-free survival, distant recurrence-free survival, and the incidence of adverse events throughout the treatment period. The study will also measure the "lead time" between ctDNA positivity and radiologic or clinical recurrence, which may provide insight into the biological dynamics of disease relapse. Furthermore, researchers will evaluate ctDNA clearance at the completion of abemaciclib therapy, as ctDNA clearance may serve as an early indicator of treatment efficacy. Collectively, these results are expected to clarify the clinical utility of ctDNA-guided therapy escalation and to inform future strategies for preventing recurrence in early breast cancer.

Interventions

• Drug Abemaciclib 150 MG Oral Tablet
  Adding abemaciclib for 2-year with endcrine treatment

Primary outcome measures

• ctDNA clearance rate [Time frame: Within 2 years]

Secondary outcome measures (4)

• Invasive disease-free survival (IDFS) [Time frame: through study completion, an average of 3 year]
• Distant recurrence-free survival (DRFS) [Time frame: through study completion, an average of 3 year]
• Lead time from ctDNA positivity to clinical recurrence [Time frame: through study completion, an average of 2 year]
• Incidence of adverse events [Time frame: up to 2 years]

Eligibility criteria

Inclusion criteria

• Histologically confirmed invasive breast cancer.
• ctDNA-positive after completion of definitive local/systemic therapy.
• Definitive breast surgery performed; axillary node status confirmed.
• HR-positive, HER2-negative disease.
• Tumor and nodal status meet predefined pathological risk criteria.
• ECOG PS 0 - 1.
• No bilateral breast cancer.
• Adequate recovery from prior therapy and acceptable organ function.
• No distant metastasis before registration.
• Appropriate contraception; informed consent obtained.

Exclusion criteria

• Active second malignancy.
• Prior CDK4/6 inhibitor use.
• Recent major surgery or active infection.
• Uncontrolled hypertension or significant cardiac disease.
• Recent thromboembolic events.
• Interstitial lung disease or active pneumonitis.
• Unrecovered toxicities from prior treatment.
• Active HIV, HBV, or HCV infection.
• Pregnancy or breastfeeding.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Japan · 1 center

• Nagoya City University — Nagoya

Identifiers

NCT: NCT07292207 · NCU-003-Abema · NCU

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗